Arbutus Biopharma Files 8-K on Shareholder Vote Matters

Ticker: ABUS · Form: 8-K · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, shareholder-vote, corporate-event

TL;DR

Arbutus Biopharma filed an 8-K for a shareholder vote on May 21st.

AI Summary

Arbutus Biopharma Corp. filed an 8-K on May 23, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing indicates a change in the company's reporting status or a significant corporate event requiring disclosure.

Why It Matters

This filing signals that Arbutus Biopharma has held or is preparing to hold a shareholder vote on important corporate matters, which could impact the company's future direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of a shareholder vote, not indicative of immediate financial distress or significant operational changes.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Arbutus Biopharma's security holders?

The filing does not specify the exact matters submitted for a vote, only that such matters were reported on as of May 21, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on May 21, 2025.

What is the principal executive office address for Arbutus Biopharma Corp?

The principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.

What was Arbutus Biopharma Corp. formerly known as?

Arbutus Biopharma Corp. was formerly known as TEKMIRA PHARMACEUTICALS Corp.

What is the filing date of this 8-K report?

This 8-K report was filed on May 23, 2025.

From the Filing

0001447028-25-000104.txt : 20250523 0001447028-25-000104.hdr.sgml : 20250523 20250523160810 ACCESSION NUMBER: 0001447028-25-000104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25982222 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 abus-20250521.htm 8-K abus-20250521 FALSE 0001447028 701 Veterans Circle Warminster Pennsylvania 0001447028 2025-05-21 2025-05-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  May 21, 2025   Arbutus Biopharma Corp oration (Exact name of registrant as specified in its charter)   British Columbia, Canada   001-34949   98-0597776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   701 Veterans Circle Warminster , Pennsylvania   18974 (Address of principal executive offices)   (Zip Code)   ( 267 ) 469-0914 Registrant’s telephone number, including area code     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o Item 5.07. Submission of Matters to a Vote of Security Holders. On May 21, 2025 , Arbutus Biopharma Corporation (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted and: (1) elected each of the Company’s nominees for director; (2) approved, by non-binding advisory vot

View on Read The Filing